Abstract: A group of functionalized macrocyclic polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes for cancer.

Abstract: Complexes of bicyclopolyazamacrocyclophosphonic acid compounds with a metal ion, e.g. .sup.153 Sm, .sup.177 Lu, .sup.159 Gd, .sup.149 Pm, .sup.140 La, .sup.175 Yb, .sup.166 Ho, .sup.90 Y, .sup.47 Sc, .sup.186 Re, .sup.188 Re, .sup.142 Pr, .sup.99m Tc, .sup.67 Ga, .sup.68 Ga, .sup.105 Rh, .sup.97 Ru, .sup.111 In, .sup.113m In or .sup.115m In ion, are disclosed. The complexes can be covalently attached to a biologically active molecule, e.g. an antibody or antibody fragment, to form conjugates. The complexes and conjugates are useful as radiopharmaceutical agents for therapy and/or diagnostic purposes.

Abstract: Compositions and method for therapeutic and/or diagnostic treatment of soft tissue tumors in mammals using certain metals ions that are particle-emitting radionuclides, e.g. .sup.153 Sm, complexed with a phenolic carboxylate ligand, e.g. 2,6-bis[N,N-bis(carboxymethyl)aminomethyl]-4-(acetamido)phenol, (bis-IDA), is described.

Abstract: A group of functionalized amine chelants having ortho ligating functionality that form complexes with rare-earth type metal ions are disclosed. The chelants possess the general formula ##STR1## wherein R.sup.'1, R.sup.'2, R.sup.'3, R.sup.'4, R.sup.'5 and R.sup.'6, Z' and X are all defined in the specification. In addition certain of the chelant-radionuclide complexes can be effectively employed in compositions useful as therapeutic and/or diagnostic agents for calcific tumors and/or relief of bone pain.

Abstract: Oral compositions and methods effective in promoting oral hygiene containing in an effective amount at least one cyclic alkylamine or cyclic amine as an antiplaque and/or antigingivitis agent.

Abstract: Oral compositions containing an effective amount as an anticalculus agent at least one cyclic alkylamine or cyclic amine in the presence or absence of a cationic antimicrobial agents.

Abstract: A method for therapeutic and/or diagnostic treatment of soft tumor carcinoma in mammals using certain metals or particle-emitting radionuclides complexed with hydroxyethylethylenediaminetriacetic acid is described.

Abstract: Particle-emitting radionuclides, e.g. Gd-159, Ho-166, Lu-177 and Yb-175, have been complexed with organic aminoalkylenephosphonic acids. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors or the relief of bone pain in animals.

Abstract: Radioactive compositions containing a calcific matrix and methods for using the compositions for therapeutic radiation treatment including rheumatoid arthritis are disclosed.

Abstract: An oral composition for suppressing mouth odors comprising from about 0.001 to about 10 percent by weight of a copper salt and from about 0.001 to about 10 percent by weight phytic acid or a physiologically acceptable salt thereof. A cationic antimicrobial compound is added to the oral composition to aid in the prevention of plaque formation and gingivitis provided the oral composition contains from about 0.01 to about 20 percent by weight of a compatibilizing agent.

Abstract: A stabilized radionuclide-colloid composition useful in therapeutic radiation ablation therapies is disclosed. The composition contains a viscosity modifier layered mixed metal hydroxide and optionally an ion exchange medium to stabilize the radioactive colloid.

Abstract: Magnesium is separated from magnesium slag containing radioactive thorium and its daughters by solubilizing magnesium from magnesium slurry using carbon dioxide and separating magnesium from magnesium slurry containing thorium and its daughters by filtering. The process concentrates the radioactive thorium and its radioactive daughters from the magnesium slag and reduces the volume of the radioactive waste that requires disposal.

Abstract: A stabilized radionuclide-colloid composition useful in therapeutic radiation ablation therapies is disclosed. The composition contains a viscosity modifier layered mixed metal hydroxide and optionally an ion exchange medium to stabilize the radioactive colloid.

Abstract: Radioactive high molecular weight metal-binding protein compositions and a method for therapeutic radiation treatment including the treatment of rheumatoid arthritis comprising injection of a radioactive high molecular weight metal-binding protein compositions are disclosed.

Abstract: Particle-emitting radionuclides, e.g. Gd-159, Ho-166, Lu-177 and Yb-175, have been complexed with organic aminoalkylenephosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors in animals and in relief of bone pain.

Abstract: Particle emitting radionuclides, e.g. X-90, have been complexed with certain macrocyclic aminophosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions and formulations for the therapeutic treatment of calcific tumors and the relief of bone pain in animals.

Abstract: Radiolabeled colloid compositions and a method for the preparation of radionuclide-colloid compositions useful in the treatment of rheumatoid arthritis are disclosed. A radionuclide selected from the group consisting of Sm-135, Ho-166, In-155m, Y-90, Gd-159 La-140, Lu-177, or Yb-175 is sorbed to a previously prepared iron-hydroxide colloid. The radiolabeled colloid compositions are comprised of spherical aggregations containing greater than 50% of the radioactive metal in iron-hydroxide particles. The method produces stable radionuclide iron-hydroxide compositions which are useful in therapeutic procedures such as radiation synovectomy.

Abstract: Particle emitting radionuclides, e.g. Samarium-153, have been complexed with certain macrocyclic aminophosphonic acids wherein the nitrogen and phosphorus are interconnected by an alkylene group or substituted alkylene group. These complexes have been found useful in compositions and formulations for the therapeutic treatment of calcific tumors in animals.

Abstract: The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, Holmium-166 and Yttrium-90 and at least one macrocyclic aminophosphonic acid ligand containing the 1,4,7,10-tetraazacyclododecane moiety, or a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.

Abstract: High purity ethylenediaminetetra(methylenephosphonic acid) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonic acid) are prepared by dissolving the aminomethylenephosphonic acid in an aqueous base, acidifying with a mineral acid at an elevated temperature to precipitate the crystals, maintaining the solution at an elevated temperature for a period of time sufficient to assure crystallization, cooling to a lower temperature and maintaining at that temperature for a time sufficient to precipitate the crystals and filtering the resulting crystals at that temperature, washing the crystals with water and recovering the desired high purity aminophosphonic acid. The ethylenediaminetetra(methylenephosphonic acid) is obtained in a purer state during its synthesis if the crystals are filtered hot without prior cooling.